In-Body CAR-T: could this be the future of blood cancer treatment?

NCT ID NCT07362602

Not yet recruiting Disease control Sponsor: The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new type of CAR-T therapy for B-cell blood cancers like lymphoma and leukemia. Instead of removing a patient's immune cells, modifying them in a lab, and infusing them back, this drug delivers genetic instructions directly into the body using tiny fat particles (LNPs). The goal is to reprogram the patient's own T cells to attack cancer cells marked by CD20. The study will enroll 47 adults to check safety and find the right dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mRNA-LNP in vivo CAR-T drug targeting CD20
What this could lead to: If successful, this could lead to a simpler, faster, and more affordable CAR-T therapy for B-cell blood cancers, avoiding the need to remove and modify cells outside the body.
What could go wrong: This is a very early (Phase 1) exploratory study with only 47 participants. It may not show strong effectiveness, and safety in humans is still unknown. The approach is novel and unproven in clinical settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CD20+ B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm lymphoid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCIES

More trials for these conditions

Other studies related to the condition(s) this trial covers.